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Objective. While the role of antiphospholipid antibodies in activating endothelial cells has been extensively stud-
ied, the impact of these antibodies on the adhesive potential of leukocytes has received less attention. This study 
was undertaken to investigate the extent to which antiphospholipid syndrome (APS) neutrophils adhere to resting 
endothelial cells under physiologic flow conditions and the surface molecules required for that adhesion.
Methods. Patients with primary APS (n = 43), patients with a history of venous thrombosis but negative test re-
sults for antiphospholipid antibodies (n = 11), and healthy controls (n = 38) were studied. Cells were introduced into 
a flow chamber and perfused across resting human umbilical vein endothelial cells (HUVECs). Surface adhesion mol-
ecules were quantified by flow cytometry. Neutrophil extracellular trap release (NETosis) was assessed in neutrophil- 
HUVEC cocultures.
Results. Upon perfusion of anticoagulated blood through the flow chamber, APS neutrophils demonstrated 
increased adhesion as compared to control neutrophils under conditions representative of either venous (n = 8; 
P < 0.05) or arterial (n = 15; P < 0.0001) flow. At the same time, APS neutrophils were characterized by up- regulation 
of CD64, CEACAM1, β2- glycoprotein I, and activated Mac- 1 on their surface (n = 12–18; P < 0.05 for all mark-
ers). Exposing control neutrophils to APS plasma or APS IgG resulted in increased neutrophil adhesion (n = 10–11; 
P < 0.0001) and surface marker up- regulation as compared to controls. A monoclonal antibody specific for activated 
Mac- 1 reduced the adhesion of APS neutrophils in the flow- chamber assay (P < 0.01). The same monoclonal anti-
body reduced NETosis in neutrophil–HUVEC cocultures (P < 0.01).
Conclusion. APS neutrophils demonstrate increased adhesive potential, which is dependent upon the activat-
ed form of Mac- 1. In patients, this could lower the threshold for neutrophil–endothelium interactions, NETosis, and 
 possibly thrombotic events.
INTRODUCTION
Antiphospholipid syndrome (APS) is an autoimmune 
 condition of unknown cause and is defined by the presence 
of circulating antiphospholipid antibodies (aPLs; anticardiolipin, 
anti–β2- glycoprotein I [anti- β2GPI], or lupus anticoagulant [LAC]) 
(1). The morbidity and mortality of APS are significant, as patients 
carry a markedly increased risk of thrombotic events (espe-
cially stroke and deep vein thrombosis) and pregnancy loss (2). 
Beyond these disease- defining events, patients with APS may 
also develop cytopenias, heart valve damage, nephropathy, and 
cognitive dysfunction, among other complications (3). While it has 
long been recognized that circulating leukocytes play some role 
in the pathophysiology of APS, the impact of neutrophils has only 
come to light in the past few years (4). Our group and others have 
shown that APS neutrophils are prone to the exaggerated release 
of neutrophil extracellular traps (NETs), prothrombotic tangles of 
DNA, and microbicidal proteins released from dying neutrophils 
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(5). At the same time, at least some APS blood does not degrade 
NETs normally (6). Indeed, dismantling NETs with deoxyribonu-
clease (7) and preventing NET release (NETosis) via activation of 
adenosine receptors (8) has proven effective in murine models 
of APS. In further support of neutrophil hyperactivity in APS, our 
group has demonstrated that the APS neutrophil transcriptome is 
characterized by the up- regulation of a number of meta- groups, 
including a cellular defense node that includes L- selectin and 
P- selectin glycoprotein I among other adhesion molecules (9).
Beyond neutrophils, both animal models and descriptive stud-
ies of patients have demonstrated signs of smoldering endothelial 
activation in APS. For example, tissue factor activity is increased 
in carotid homogenates from mice treated with antiphospholipid 
antibody (10), which correlates with increased leukocyte–endothe-
lium interplay (11). In keeping with the latter concept, antagoniz-
ing either E- selectin or P- selectin (the key selectins expressed 
on the endothelium) is protective against thrombosis in mice; 
the same is true for strategies blocking the endothelial integrin 
ligands vascular cell adhesion molecule 1 and intercellular adhe-
sion molecule 1 (ICAM- 1) (12,13). One study has suggested that 
down- regulation of endothelial nitric oxide synthase by aPLs may 
be another important factor in increased leukocyte–endothelium 
interplay (14). Beyond these in vivo data, there is robust evidence 
in vitro that aPLs can activate endothelial cells to express tissue 
factor and adhesion molecules (15,16). Mechanistically, NF- κB, 
p38 MAPK, and Krüppel- like factors have all been implicated in 
antiphospholipid antibody–mediated activation of endothelial cells 
(17–19), demonstrating how aPLs may co- opt pathways normally 
associated with more “authentic” activating stimuli.
Mac- 1 is a heterodimeric β2 integrin especially expressed 
by myeloid- lineage cells. In its activated state, Mac- 1 mediates 
cell–cell interactions by engaging a variety of surface molecules, 
including the endothelium- expressed glycoprotein ICAM- 1. In this 
study, we focused on leukocytes and especially neutrophils (rather 
than on the endothelium) and how they contribute to heterotypic 
adhesive interactions relevant to APS. We studied blood samples 
from APS patients as well as control leukocytes conditioned with 
either APS plasma or APS IgG. We characterized leukocyte adhe-
sion to resting endothelial cells under physiologic flow conditions. 
We also considered key adhesion molecules, including Mac- 1, on 
the surface of APS neutrophils and explored their role in not just 
adhesion, but also in NETosis.
MATERIALS AND METHODS
Human subjects. Patients were recruited from rheumatology 
and hematology clinics at the University of Michigan (Supplemen-
tary Tables 1–3, available on the Arthritis & Rheumatology web site 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41057/ abstract). 
All 43 patients diagnosed as having APS fulfilled the clinical and 
laboratory criteria for APS according to the updated international 
consensus (Sydney) classification criteria (1). None of the patients 
met American College of Rheumatology revised criteria for systemic 
lupus erythematosus (20). Of the patients with APS, some were 
classified as having “obstetric APS” if they had no prior history of 
vascular thrombosis but did have APS- associated obstetric com-
plications as defined by the Sydney classification criteria (i.e., ≥3 
unexplained, consecutive spontaneous pregnancy losses; or ≥1 
unexplained fetal deaths at ≥10 weeks of gestation; or ≥1 preterm 
deliveries of a morphologically normal infant before 34 weeks of 
gestation due to severe preeclampsia, eclampsia, or features con-
sistent with placental insufficiency) (1). Eleven patients with a history 
of unprovoked venous thrombosis (VT) but with negative test results 
for aPLs, were also recruited (Supplementary Table 4, available 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41057/ abstract); 
many of these patients had genetic risk factors for VT, such as fac-
tor V Leiden heterozygosity as detailed in Supplementary Table 4.
Thirty- eight healthy controls were recruited through a posted 
flyer; exclusion criteria included history of a systemic autoimmune 
disease, active infection, and pregnancy. All 38 controls were 
screened for IgG anti- β2GPI and all had negative test results. 
Blood samples were collected by phlebotomist- performed veni-
puncture, and serum was prepared by standard methods and 
stored at –80°C until used. IgG, IgM, and IgA anti- β2GPI, as well 
as IgG and IgM anticardiolipin antibodies, were determined by 
multiplex assay on a BioPlex 2200 System (Bio- Rad). LAC was 
tested according to published guidelines (21). This study was 
reviewed and approved by the University of Michigan Institutional 
Review Board. Written informed consent was obtained from all 
participants prior to inclusion.
Preparation of human IgG. IgG was purified from 
human serum samples with a Protein G–Agarose kit according 
to the instructions of the manufacturer (Pierce). Briefly, serum 
was diluted in IgG binding buffer and passed through a protein 
G–agarose column at least 5 times. IgG was eluted with 0.1M 
glycine. This solution was neutralized with 1M Tris followed by 
overnight dialysis against phosphate buffered saline (PBS) at 
4°C. After passage through a 0.2μ filter, IgG purity was verified 
by sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis. IgG concentrations were quantified by bicinchoninic acid 
protein assay (Pierce). IgG preparations were confirmed to be 
free of endotoxin contamination as determined by a chromo-
genic endotoxin quantification kit (Pierce).
Human neutrophil purification. For neutrophil prepa-
ration, blood samples were collected into sodium citrate tubes 
by standard phlebotomy techniques. The anticoagulated blood 
was then fractionated by density- gradient centrifugation using 
Ficoll- Paque Plus (GE Healthcare). Neutrophils were further 
purified by dextran sedimentation of the red blood cell (RBC) 
layer before lysing residual RBCs with 0.2% sodium chloride. 
 Neutrophil preparations were >98% pure as confirmed by both 
flow cytometry and nuclear morphology.
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In vitro flow adhesion assays. For all flow chamber 
experiments, blood was collected into citrate tubes. A parallel- 
plate flow chamber (PPFC) with straight gaskets forming the flow 
channel (GlycoTech) was then used for in vitro flow adhesion 
assays. Briefly, a single straight gasket was placed over a human 
umbilical vein endothelial cell (HUVEC) monolayer cultured on a 
glass coverslip (22) and vacuum- sealed to the flow deck to form 
the bottom adhesion substrate of the chamber.
For some experiments, “leukocytes” were prepared by mix-
ing together the buffy coat and RBCs (after discarding plasma). 
In other cases, “neutrophils” were prepared by retrieving the 
neutrophil–RBC pellet that remained after Ficoll gradient sep-
aration. For these leukocyte and neutrophil experiments, cells 
were always brought back to their original blood volume with 
flow buffer (PBS with calcium and magnesium with 1% bovine 
serum albumin [BSA]). A total of 2 ml of whole blood, leuko-
cytes, or neutrophils was introduced into the chamber from an 
inlet  reservoir via a programmable syringe pump (KD Scientific). 
For low- shear experiments, samples were perfused across the 
HUVEC monolayer using a laminar flow profile. The wall shear 
rate (WSR; γw) was fixed by adjusting the volumetric flow rate (Q) 
through the channel according to the following equation:
where h is the channel height (127 μm) and w is the channel 
width (0.25 cm). The height of 127 μm and WSR of 200 sec-
onds−1 were chosen to approximate the flow profile within veins 
and venules. Low- shear samples were perfused over HUVECs 
for 5 minutes. For high- shear experiments, pulsatile flow was 
used in the horizontal PPFC as described previously (22). Spe-
cifically, samples were perfused over HUVEC mono layers in 
pulsatile flow at a WSR of 1,000 seconds−1 for 15 minutes 
(23–25). The flow time was chosen to ensure the same volume 
of blood passed through the chamber as for laminar/low- shear 
experiments (22). At the end of the prescribed flow time, flow 
buffer was added to the PPFC to flush out nonadherent cells.
Ten images per sample were collected along the length of the 
flow chamber using a Nikon TE2000S inverted microscope with 
a digital camera (Photometrics CoolSNAP EZ with a Sony CCD 
sensor). Results were imaged and analyzed using NIS- elements 
analysis software and ImageJ. The adherent cells were normalized 
to the control cells examined on the same day so as to minimize 
variation attributable to different batches of HUVECs. 
For experiments involving the pretreatment or conditioning of 
control leukocytes, the buffy coat/RBC sample was incubated at 
37°C for 1 hour with plasma before washing again with flow buffer. 
For blocking experiments, anti–Mac- 1 (20 μg/ml, clone CBRM1/5) 
antibody or isotype control was also included during the incubation.
Flow cytometry studies. For all flow cytometry experi-
ments, blood samples were collected into citrate tubes and imme-
diately processed. Fc blocking of cells (in whole blood) was carried 
out using Human TruStain FcX (BioLegend), according to the 
instructions of the manufacturer. Subsequently, cells (still in whole 
blood) were stained with specific antibodies for 30 minutes on ice, 
followed by immediate lysis of RBCs and fixation of leukocytes 
using eBioscience 1- step Fix/Lyse Solution. Samples were ana-
lyzed on an LSRFortessa cell analyzer (BD Biosciences) and ZE5 
cell analyzer (Bio- Rad). Further data were analyzed with FlowJo 
software (Tree Star). Specific primary antibodies were against apo-
lipoprotein H (ABS162; EMD Millipore), CD15 (W6D3; BioLegend), 
CD16 (3G8; BioLegend), CEACAM1 (283340; R&D Systems), 
CD64 (10.1; BioLegend), activated lymphocyte function–asso-
ciated antigen 1 (LFA- 1) (m24; BioLegend), activated Mac- 1 
(CBRM1/5; BioLegend), and CD62L (DREG- 56; BioLegend). 
We also used eBioscience Fixable Viability Dye eFluor 506 and 
secondary antibody Alexa Fluor 680 AffiniPure donkey anti- rabbit 
IgG (heavy and light chains) (711- 625- 152; Jackson ImmunoRe-
search). For leukocyte conditioning experiments, the sample was 
spiked with increasing concentrations of either APS or control IgG 
(10 μg/ml or 100 μg/ml), or the citrated plasma of the sample was 
discarded and replaced with heterologous control or APS plasma 
and incubated for 1 hour at 37°C before staining and flow analysis.
Toll- like receptor 4 (TLR- 4) and complement inhibition. 
Anticoagulated control blood was preincubated with 20 μM TLR- 4 
inhibitor (TAK- 242) or 10 μM C5a receptor antagonist (W- 54011) 
(both from Cayman Chemical) for 30 minutes. The sample was 
then spiked with IgG as described above and incubated for 1 hour 
at 37°C.
Quantification of NETosis. Neutrophils were labeled with 
CytoTrace Red CMTPX (5 μM; AAT Bioquest) according to the 
instructions of the manufacturer and resuspended in RPMI medium 
supplemented with 0.5% BSA and 0.5% fetal bovine serum (all 
from Gibco). Neutrophils (1.5 × 105 cells/well) were then incubated 
in 48- well plates with a preestablished monolayer of HUVECs at 
37°C. Samples were additionally treated with 100 μg/ml APS IgG 
or control IgG in the presence of anti–Mac- 1 (20 μg/ml; clone 
CBRM1/5) or isotype control. After 3 hours, Sytox green (Ther-
moFisher Scientific) was added to a final concentration of 0.2 μM 
and incubated for an additional 10 minutes. Fluorescence was 
quantified at excitation and at emission wavelengths of 485 nm 
and 520 nm, respectively, using a BioTek Cytation 5 Cell Imaging 
Multi- Mode Reader. Representative images were captured by the 
BioTek Cytation 5 reader’s 20× objective lens.
Statistical analysis. Data analysis was conducted using 
GraphPad Prism software, version 7. Normally distributed data 
were analyzed by t- tests, while skewed data were assessed by 
the Mann- Whitney test. Analysis of variance (ANOVA) with appro-
priate correction for multiple comparisons was also used where 
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indicated in the figure legend. P values less than 0.05 were con-
sidered significant.
RESULTS
Demonstration of increased adhesion under flow by 
APS neutrophils. Utilizing anticoagulated whole blood collected 
from patients with primary APS or matched healthy volunteers 
(Supplementary Tables 1–3, available at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41057/ abstract), we tested leukocyte adhe-
sion to unactivated/resting early- passage HUVECs in a PPFC 
assay. Representative images of leukocyte adhesion in the PPFC 
assay are shown in Figure 1A. Compared to control blood, we 
observed increased adhesion of APS leukocytes under high- shear 
(1,000 seconds−1)  pulsatile flow conditions, as might be found in 
arteries or the arterioles (Figure 1B). Similar results were observed 
when blood was passed through the chamber under lower- shear 
(200 seconds−1) laminar flow, as would be found in the venous 
system (Figure 1B). If the increased adhesion were being driven 
by factors inherent to the leukocytes themselves, we reasoned 
that a similar phenotype would be observed if plasma (along with 
the cytokines and autoantibodies that might activate the HUVECs) 
were discarded. Indeed, isolated APS leukocytes, in the absence 
of plasma, still adhered in exaggerated manner to HUVECs (under 
both high- and low- shear flow conditions) (Figure 1C). Finally, we 
removed not just plasma, but also peripheral blood mononuclear 
cells by spinning the blood through a density gradient. Again, we 
observed increased adhesion of neutrophils to HUVECs as com-
pared to controls (Figure 1D). In summary, these data reveal that 
leukocytes, and specifically neutrophils, demonstrate increased 
adhesion to unstimulated HUVECs in the context of various flow 
profiles. The phenotype persisted even after plasma was dis-
carded, which is consistent with an inherent role for neutrophils in 
the adhesive interaction.
Up- regulation of adhesion molecules on the surface 
of APS neutrophils. In an effort to understand what seemed to 
be an inherent increase in APS neutrophil adhesion, we evaluated 
Figure 1. Antiphospholipid syndrome (APS) neutrophils showing increased adhesion in multiple flow profiles. Adhesion was measured under 
either pulsatile high- shear (1,000 seconds−1) conditions or laminar low- shear (200 seconds−1) conditions. A, Schematic illustration of the parallel- 
plate flow chamber (left) and a representative image (right) showing adhesion of APS leukocytes (arrowheads). Original magnification × 20. B, 
Perfusion of anticoagulated whole blood samples from healthy controls (n = 18 for high shear and n = 9 for low shear) or patients with APS (n = 
15 for high shear and n = 8 for low shear) through the flow chamber and quantification of adherent cells. **** = P < 0.0001 versus controls, by 
Mann- Whitney test; * = P < 0.05 versus controls, by t- test. C, Perfusion of isolated and resuspended (in flow buffer; plasma discarded) control 
leukocytes (n = 10 for high shear and n = 7 for low shear) or APS leukocytes (n = 8 for high shear and n = 5 for low shear) through the flow 
chamber and quantification of adherent cells. * = P < 0.05 versus controls, by Mann- Whitney test. D, Perfusion of isolated and resuspended 
(in flow buffer) control neutrophils (n = 5) or APS neutrophils (n = 5) through the flow chamber and quantification of adherent cells. * = P < 0.05 
versus controls, by t- test. In B–D, symbols represent individual samples; horizontal lines show the mean. HUVECs = human umbilical vein 
endothelial cells.
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the surface expression of various adhesion molecules on the neu-
trophil surface (Figure 2A). As ICAM- 1 is known to be expressed 
even by resting HUVECs, we reasoned that β2 integrin family 
members (which are well known to interact with ICAM- 1) might be 
up- regulated on APS neutrophils, thus mediating the increased 
adhesion. While we observed no difference in the activated form 
of β2 integrin LFA- 1 (Figure  2B), the activated form of another 
β2 integrin, Mac- 1, was robustly up- regulated on the surface 
of APS neutrophils (Figure 2C). An evaluation of other potential 
markers of neutrophil activation revealed no significant difference 
in CD62L (L- selectin), but did reveal up- regulation of both CD64 
and CEACAM1 (Figures  2D–F). Interestingly, autoantigen β2GPI 
was also present at increased levels on the surface of APS neutro-
phils  (Figure 2G). In summary, these data demonstrate increased 
expression of activated Mac- 1, but not activated LFA- 1, on the 
neutrophil surface, which correlates with the up- regulation of other 
neutrophil activation markers such as CD64 and CEACAM1.
Dependence of APS IgG–mediated up- regulation of 
Mac- 1 on neutrophils on TLR- 4 and complement ana-
phylatoxin receptors. Previous work by our group has demon-
strated that NETosis can be triggered from control neutrophils by 
incubation with either APS serum or APS IgG (5). In the present 
study we explored whether adhesion molecules were also up- 
regulated by similar treatment (Figure 3A). When we “conditioned” 
control blood cells with APS plasma, we did not find increased 
expression of activated LFA- 1 on the surface of neutrophils 
(Figure 3B). In contrast, there was a striking increase in surface 
expression of activated Mac- 1 (Figure  3C). We also found evi-
dence of shedding of CD62L from neutrophils and up- regulation 
of both CD64 and CEACAM1 (Figures 3D–F). β2GPI was meas-
ured, but was not significantly up- regulated  (Figure 3G). We then 
conditioned control blood with IgG purified from patients with pri-
mary APS; under these conditions we observed up- regulation of 
activated Mac- 1 on neutrophils (Figure 4A), along with shedding 
of CD62L (Figure 4B). Having previously observed that APS IgG–
mediated NETosis is dependent on TLR- 4, we assessed that same 
pathway in the context of Mac- 1 activation. Indeed, the TLR- 4 
signaling inhibitor TAK- 242 prevented APS IgG from up- regulating 
activated Mac- 1 on neutrophils (Figure 4C). We reasoned that we 
might also find a role for the complement cascade in neutrophil 
activation. When blood was treated with a C5a receptor inhib-
itory antibody, up- regulation of activated Mac- 1 on neutrophils 
was blunted (Figure 4D). In summary, these data together indicate 
Figure 2. Increased expression of activated Mac- 1 and other adhesion molecules on antiphospholipid syndrome (APS) neutrophils. Flow 
cytometry was performed after treating anticoagulated whole blood samples with fluorescently labeled antibodies. Mean fluorescence 
intensity (MFI) was normalized to controls run in the same batch. A, Cell sorting plots showing gating strategy for identification of neutrophils 
in whole blood. B–G, Up- regulation of activated lymphocyte function–associated antigen 1 (LFA- 1) (B), activated Mac- 1 (C), CD62L (D), CD64 
(E), CEACAM1 (F), and β2- glycoprotein I (β2GPI). (G). In B–E, n = 18 for control samples and n = 20 for APS samples. In F and G, n = 8 for 
control samples and n = 12 for APS samples. In B–G, symbols represent individual samples; horizontal lines show the mean. * = P < 0.05 versus 
controls, by t-test. Differences in B and D were not significant.
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that control neutrophils up- regulate activated Mac- 1 in response 
to conditioning with either APS plasma or APS IgG and that this 
up- regulation requires TLR- 4 and the C5a receptor.
Requirement of activated Mac- 1 for increased 
 adhesion of APS neutrophils. Having found that APS 
plasma up- regulates Mac- 1 on the surface of control neutro-
phils, we reasoned that this up- regulation might be directly 
responsible for increased neutrophil adhesion. Indeed, APS 
plasma–treated cells, but not control plasma–treated cells, 
demonstrated increased adhesion under both high- shear 
and low- shear flow conditions (Figure  5A). Furthermore, a 
monoclonal antibody specific for the activated form of Mac- 1 
 effectively neutralized adhesion in the context of conditioning 
with APS plasma, but had no effect in the setting of control 
plasma  (Figure 5B). To determine whether the ability of plasma 
to stimulate cell adhesion was unique to patients with APS or 
whether the phenotype might extend to any patient with a his-
tory of thrombosis, we recruited 11 patients with a history of 
unprovoked VT but with test results negative for aPLs (Sup-
plementary Table 4, available at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41057/ abstract).
When compared to plasma samples from healthy controls, 
plasma samples from the VT cohort triggered no increase in cell 
adhesion (Figure 5C). Similar to this finding, conditioning  neutrophils 
with plasma from the VT cohort did not alter  levels of activated 
Mac- 1, CD62L, or CD64 (Figures 5D–F) on the neutrophil surface. 
Finally, we asked whether the increased cell adhesion triggered by 
APS plasma might be limited to patients with a history of “throm-
botic APS” (i.e., at least 1 documented arterial, venous, or small 
vessel thrombotic event). Interestingly, we observed increased 
adhesion whether the plasma was collected from patients with 
“thrombotic APS” or patients with purely “obstetric APS” (Sup-
plementary Figure 1, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41057/ 
abstract). In summary, these data demonstrate that antagonizing 
the activated form of Mac- 1 is sufficient to reduce APS- relevant 
adhesion to levels seen in controls.
Requirement of activated Mac- 1 for NETosis by APS 
neutrophils bound to endothelial cells. Given evidence by 
our group and others (5,26) that NETosis proceeds most efficiently 
upon cell adhesion, we investigated whether the aforementioned 
antibody targeting activated Mac- 1 might mitigate NETosis. 
Figure 3. Increased expression of activated Mac- 1 and other adhesion molecules when control neutrophils are conditioned with APS plasma. A, 
Conditioning of control leukocytes with heterologous control plasma or APS plasma and incubation with fluorescently labeled antibodies. MFI was 
normalized to controls run in the same batch. B, No increased expression of activated LFA- 1 on the neutrophil surface (differences not significant, 
by t- test). C, Increase in surface expression of activated Mac- 1. ** = P < 0.01 versus controls, by t- test. D, Shedding of CD62L from neutrophils. 
*** = P < 0.001 versus controls, by t- test. E, Up- regulation of CD64. * = P < 0.05 versus controls, by t- test. F, Up- regulation of CEACAM1. 
* = P < 0.05 versus controls, by Mann- Whitney test. G, Up- regulation of β2GPI (differences not significant, by t- test). In B–G, symbols represent 
individual samples (n = 9 for controls and n = 12 for APS); horizontal lines show the mean. See Figure 2 for definitions.
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To test this, we adhered vital dye–labeled neutrophils to resting 
HUVECs and then tracked NETosis in real time via the loss of vital 
dye and the local release of decondensed DNA (Figure 6A). As 
compared to isotype treatment, the Mac- 1 monoclonal antibody 
significantly neutralized NETosis in response to APS IgG, but not 
phorbol myristate acetate (Figure  6B). In summary, these data 
demonstrate that inhibition of the activated form of Mac- 1 can 
neutralize NETosis, at least in the context of APS.
DISCUSSION
While there are many studies characterizing the activated 
endothelium in APS (11,15), comparatively little is known about the 
adhesive nature of circulating cells (27). In this study we  examined 
the adhesive potential of APS leukocytes and, particularly, neutro-
phils. We found enhanced adhesion of APS neutrophils to resting 
HUVECs irrespective of the flow conditions (Figures  1B and C). 
Notably, this functional increase in adhesion was observed in the 
context of up- regulated adhesion molecules on the neutrophil sur-
face, including CD64, CEACAM1, and the activated form of Mac- 1 
(Figure 2). These findings did not extend to patients with a history of 
unprovoked VT and negative test results for aPLs  (Figures 5C–F), 
suggesting that these results may represent relatively unique fea-
tures of APS. Of note, all flow experiments were performed in the 
presence of RBCs, which are known to stabilize leukocyte adhesion, 
thereby more closely modeling conditions observed in vivo (28).
In addition to thrombosis of arteries, veins, and small vessels, 
another hallmark of APS is pregnancy- related morbidity. There is 
evidence that obstetric complications of APS have distinct patho-
physiology as compared to thrombotic APS (29); however, recent 
data have suggested that up to 60% of patients who begin with a 
diagnosis of “obstetric APS” will eventually develop a thrombotic 
event (30). While the cohort tested here was relatively enriched for 
patients with thrombotic complications, we identified and tested 
8 patients with a history of only obstetric morbidity (see defini-
tion in Methods). Interestingly, these patients with obstetric APS 
Figure  4. Increased expression of activated Mac- 1 on control neutrophils occurring in a Toll- like receptor 4 (TLR- 4)– and complement- 
dependent manner through exposure to purified APS IgG. Control leukocytes were treated with control or APS IgG as indicated. Activated Mac- 
1 and CD62L were quantified by flow cytometry. A, Up- regulation of activated Mac- 1. * = P < 0.05 by one- way analysis of variance (ANOVA) 
with correction for multiple comparisons by the Holm- Sidak method (n = 4 independent experiments). B, Shedding of CD62L. ** = P < 0.01; 
*** = P < 0.0001 by one- way ANOVA with correction for multiple comparisons by the Holm- Sidak method (n = 4 independent experiments). 
C, Control leukocytes treated with control or APS IgG (100 μg/ml) in the presence or absence of TLR- 4 inhibitor (Inh.). Activated Mac- 1 was 
quantified by flow cytometry. * = P < 0.05; *** = P < 0.001 by one- way ANOVA with correction for multiple comparisons by the Holm- Sidak method 
(n = 8 independent experiments). D, Control leukocytes treated with control or APS IgG (100 μg/ml) in the presence or absence of C5a receptor 
(C5aR) inhibitor. Activated Mac- 1 was quantified by flow cytometry. *** = P < 0.001 by one- way ANOVA with correction for multiple comparisons 
by the Holm- Sidak method (n = 7 independent experiments). Values are the mean ± SEM. See Figure 2 for other definitions.
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were indistinguishable from patients with a history of thrombotic 
events in terms of neutrophil adhesion (Supplementary Figure 1, 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41057/ abstract). 
We hope that further research of disease models will allow us to 
understand the extent to which activated Mac- 1 may be a direct 
mediator of thrombotic (versus obstetric) pathophysiology.
In our previous study, we found that inhibition of TLR- 4 sig-
naling could mitigate APS IgG–mediated NETosis (5). This is in 
addition to other studies demonstrating that TLR- 4 deficiency 
protected mice from APS in vivo, and that neutrophil TLR- 4 sup-
ported phagocytosis and reactive oxygen species production by 
APS neutrophils (10,31). We demonstrated that the TLR- 4 inhib-
itor TAK- 242 prevented APS IgG from up- regulating activated 
Mac- 1 on neutrophils (Figure  4C). These data support further 
investigation of TLR- 4 signaling as a potential therapeutic target 
in APS. Similar to the TLR- 4 pathway, complement contributes 
to neutrophil activation in many contexts. Here we demonstrated 
that inhibition of C5a receptor attenuates the up- regulation of 
activated Mac- 1 on APS IgG–stimulated neutrophils (Figure 4D). 
These data are consistent with previous studies demonstrating 
that C5a receptor contributes to up- regulation of Mac- 1 (32,33).
Despite extensive CD62L shedding in control neutrophils 
conditioned with APS plasma (Figure 3D), CD62L shedding was 
not detected at a significant level in neutrophils freshly isolated 
from patients with APS (Figure  2D). One possibility is that the 
patient neutrophils have had time to up- regulate CD62L expres-
sion, thereby effectively compensating for shedding. In support of 
this idea, CD62L was up- regulated at the gene level in our recent 
transcriptomic profiling of APS neutrophils (9). Alternatively, it is 
possible that neutrophils that have shed CD62L in vivo are strongly 
activated to the point that they have preferentially left circulation, 
thereby being unavailable for our analysis. Interestingly, we also 
detected increased surface expression of the APS autoanti-
gen β2GPI on the surface of APS neutrophils by flow cytometry 
Figure 5. Increased adhesion of APS leukocytes mediated by activated Mac- 1. Control leukocytes were incubated with heterologous control 
or APS plasma, resuspended in flow buffer, and perfused through the flow chamber. Adherent cells were quantified. A, Increased adhesion of 
APS plasma–treated cells. *** = P < 0.001 versus controls, by t- test. B, Conditions similar to those in A, except with the addition of a blocking 
antibody for activated Mac- 1 to some samples. ** = P < 0.01 by one- way analysis of variance (ANOVA) with correction for multiple comparisons 
by the Holm- Sidak method. C, Conditions similar to those in A, except that control leukocytes were incubated with heterologous control 
plasma or plasma from patients with a history of unprovoked venous thrombosis (VT) and negative test results for antiphospholipid antibody. 
The leukocytes were then resuspended in flow buffer and perfused through the flow chamber. Adherent cells were quantified. D–F, Conditions 
similar to those in Figure 3, except that control leukocytes were conditioned with heterologous control plasma or VT plasma and incubated 
with fluorescently labeled antibodies, followed by quantification of the MFI fold change in activated Mac- 1 (D), CD62L (E), and CD64 (F) in 
VT plasma–conditioned cells relative to controls run in the same batch. Differences in C–F were not significant, by t- test. Symbols represent 
individual samples; horizontal lines indicate the control value (set as 1). See Figure 2 for other definitions.
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 (Figure 2G), which is in line with our 2017 study demonstrating a 
4.5- fold increase in β2GPI gene expression in APS neutrophils (9). 
It should be noted that at least one other group has demonstrated 
similar β2GPI surface and expression phenotypes in circulating 
APS monocytes (34,35).
Blocking experiments demonstrated that the adhesion of 
APS neutrophils is at least partially mediated by activated Mac- 1 
(Figure 5B). Interestingly, we also showed that APS IgG–mediated 
NETosis was Mac- 1 dependent (Figure 6). This latter finding is sim-
ilar to a study by Neeli et al, who showed that Mac- 1 was required 
for both hypercitrullination of histones and NETosis in response to 
lipopolysaccharide (LPS) stimulation (26). Of note, both LPS and 
APS IgG activate neutrophils via TLR- 4 (5). Taken together, the 
data presented in this study reveal a previously unknown role for 
activated Mac- 1 in the adhesion and NETosis of APS neutrophils.
In the general population, numerous study findings have sug-
gested a link between Mac- 1, neutrophils, and endothelium in 
thrombotic vascular diseases (36–38). For example, significant up- 
regulation of Mac-1 by neutrophils has been detected at the time 
of myocardial infarction and for up to 1 week after the event (39). In 
another study, neutrophils from myocardial infarction patients dis-
played enhanced adhesion to endothelial cells ex vivo, which could 
be reduced by blocking Mac- 1 (40). In patients with acute ischemic 
stroke, there was significant up- regulation of neutrophil Mac- 1 
immediately after the event, and persisting into the subacute phase 
of the stroke (41). In patients with venous thromboembolism, 
increased adhesive potential of neutrophils was associated with a 
higher rate of recurrence (42). As indicated in Supplementary Table 1 
(http://onlin elibr ary.wiley.com/doi/10.1002/art.41057/ abstract), 
the average time from last thrombotic event to blood collection 
for patients with APS included in this study was approximately 
4.5 years. One might hypothesize that up- regulation of activated 
Mac- 1 is detected only acutely (i.e., at the time of thrombosis) 
for persons in the general population, but remains undetected in 
patients with APS, which is potentially consistent with the life- long 
anticoagulation that such patients require. To further explore this 
question, it will be necessary to build longitudinal APS cohorts and 
study them alongside cohorts from the general population.
Beyond activated Mac- 1, we also observed consistent up- 
regulation of CD64 on the surface of APS neutrophils (Figure 2E). 
This is somewhat reminiscent of studies of patients with sickle 
cell disease. Sickle cell neutrophils demonstrate increased levels 
of CD64 and increased adhesion to endothelial cells, with some 
evidence that CD64 directly contributes to the adhesion (43,44). 
Future studies should investigate whether this surface molecule, 
typically thought of as an IgG receptor, might also play a role in 
APS neutrophil adhesion. CEACAM1 (CD66a) expression was 
also consistently up- regulated on APS neutrophils (Figure  2F). 
Interestingly, there are studies to suggest that signaling through 
CEACAM1 (and potentially other CEACAM family members) 
results in activation of Mac- 1 and increased adhesion to endothe-
lial cells (45–48). At the same time, recent reports (predominantly 
in mice) have suggested that CEACAM1 may have inhibitory func-
tions, protecting against neutrophil hyperactivity and neutrophil- 
mediated tissue damage. For example, CEACAM1 protected 
against ischemic stroke by inhibiting matrix metalloproteinase 
9 (49,50). CEACAM1- deficient mice also formed larger carotid 
thrombi in a ferric chloride injury model, suggesting that CEACAM1 
may inhibit arterial thrombus (51). Thus, this very interesting 
 molecule seems to warrant further study in APS.
Figure 6. Necessary activation of Mac- 1 for regulation of antiphospholipid syndrome (APS) IgG–mediated neutrophil extracellular trap release 
(NETosis). A, Fluorescence intensity showing live cells (stained with CytoTrace Red) and extracellular DNA (stained with Sytox green) in samples 
stimulated with control IgG (top), APS IgG (middle), or phorbol myristate acetate (PMA; bottom). Bars = 100 μm. B, Quantification of NETosis 
as measured by fluorescence intensity of Sytox green in cells stimulated as indicated in the presence or absence of antibodies to Mac-1. Bars 
show the mean ± SEM. ** = P < 0.01; **** = P < 0.0001 by one- way analysis of variance with correction for multiple comparisons by the Holm- 
Sidak method (n = 4 independent experiments).
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In conclusion, our study has revealed a novel role for acti-
vated Mac- 1 in regulating APS neutrophils and NETosis, and hints 
at a role for Mac- 1 in APS pathophysiology. While Mac- 1 can be 
considered as a therapeutic target in APS, mutations in CD11b 
are a well- recognized risk factor for lupus (52), and many, but not 
all, mouse studies have suggested that CD11b deficiency has the 
potential to exacerbate autoimmunity (52–55). Also, since Mac- 1 
binds to a variety of ligands, selective inhibition of specific Mac- 1 
adhesive interactions could emerge as a potential therapeutic strat-
egy. For example, one proof- of- concept study has demonstrated 
that targeted inhibition of the Mac- 1–CD40L interaction improved 
bacterial clearance and survival in a polymicrobial model of sepsis 
(56). Another innovative approach has involved the utilization of 
small- molecule Mac- 1 agonists. These agonists tend to induce an 
intermediate- affinity conformation in Mac- 1 (57), which may permit 
neutrophil adhesion, with less potential for endothelial damage. 
Indeed, a partial Mac- 1 agonist not only protected MRL/lpr mice 
from end- organ injury, but also enhanced endothelium- dependent 
vasorelaxation and thereby demonstrated an overall vasoprotec-
tive effect (58). Taken together, these study findings indicate that 
targeting Mac- 1 might indeed be feasible and emphasize the need 
for future research in patients with APS.
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